Innoviva Basic EPS 2010-2024 | INVA
Innoviva basic eps from 2010 to 2024. Basic eps can be defined as a company's net earnings or losses attributable to common shareholders per basic share basis.
| Innoviva Annual Basic EPS |
| 2023 |
$2.75 |
| 2022 |
$3.07 |
| 2021 |
$3.24 |
| 2020 |
$2.21 |
| 2019 |
$1.55 |
| 2018 |
$3.92 |
| 2017 |
$1.25 |
| 2016 |
$0.54 |
| 2015 |
$-0.16 |
| 2014 |
$-1.50 |
| 2013 |
$-1.67 |
| 2012 |
$-0.20 |
| 2011 |
$-1.41 |
| 2010 |
$-1.16 |
| 2009 |
$-1.35 |
| Innoviva Quarterly Basic EPS |
| 2024-06-30 |
$-0.55 |
| 2024-03-31 |
$0.58 |
| 2023-12-31 |
$0.96 |
| 2023-09-30 |
$1.26 |
| 2023-06-30 |
$0.02 |
| 2023-03-31 |
$0.51 |
| 2022-12-31 |
$-0.98 |
| 2022-09-30 |
$3.81 |
| 2022-06-30 |
$0.01 |
| 2022-03-31 |
$0.23 |
| 2021-12-31 |
$0.26 |
| 2021-09-30 |
$1.04 |
| 2021-06-30 |
$1.01 |
| 2021-03-31 |
$0.93 |
| 2020-12-31 |
$0.52 |
| 2020-09-30 |
$0.28 |
| 2020-06-30 |
$0.76 |
| 2020-03-31 |
$0.65 |
| 2019-12-31 |
$0.46 |
| 2019-09-30 |
$0.39 |
| 2019-06-30 |
$0.37 |
| 2019-03-31 |
$0.33 |
| 2018-12-31 |
$2.62 |
| 2018-09-30 |
$0.47 |
| 2018-06-30 |
$0.54 |
| 2018-03-31 |
$0.29 |
| 2017-12-31 |
$0.54 |
| 2017-09-30 |
$0.22 |
| 2017-06-30 |
$0.33 |
| 2017-03-31 |
$0.16 |
| 2016-12-31 |
$0.23 |
| 2016-09-30 |
$0.14 |
| 2016-06-30 |
$0.13 |
| 2016-03-31 |
$0.04 |
| 2015-12-31 |
$0.04 |
| 2015-09-30 |
$-0.04 |
| 2015-06-30 |
$-0.07 |
| 2015-03-31 |
$-0.09 |
| 2014-12-31 |
$-0.12 |
| 2014-09-30 |
$-0.19 |
| 2014-06-30 |
$-0.57 |
| 2014-03-31 |
$-0.62 |
| 2013-12-31 |
$-0.47 |
| 2013-09-30 |
$-0.44 |
| 2013-06-30 |
$-0.37 |
| 2013-03-31 |
$-0.39 |
| 2012-12-31 |
$-0.33 |
| 2012-09-30 |
$-0.37 |
| 2012-06-30 |
$-0.42 |
| 2012-03-31 |
$1.01 |
| 2011-12-31 |
$-0.45 |
| 2011-09-30 |
$-0.37 |
| 2011-06-30 |
$-0.31 |
| 2011-03-31 |
$-0.28 |
| 2010-12-31 |
$-0.24 |
| 2010-09-30 |
$-0.29 |
| 2010-06-30 |
$-0.28 |
| 2010-03-31 |
$-0.35 |
| 2009-12-31 |
$-0.34 |
| 2009-09-30 |
$-0.35 |
| 2009-06-30 |
$-0.35 |
| 2009-03-31 |
$-0.31 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$1.222B |
$0.310B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
